Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02461771 · ClinicalTrials.gov registry record · Phase 1
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD
A Phase 1 study, sponsored by Apellis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT02461771 is a Phase 1 study that has completed, run by Apellis Pharmaceuticals. The registered enrollment target is 13 participants.
The verdict
NCT02461771, a Phase 1 study, has completed, sponsored by Apellis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The objective of this study is to provide initial safety, tolerability and pharmacokinetics information of intravitreal administration of pegcetacoplan in order to support further development into larger Phase II studies for treatment of patients with AMD.
Interventions
- DRUG Pegcetacoplan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2015-01-28 |
| Est. Completion | 2016-03-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02461771
The ClinicalTrials.gov registry entry for NCT02461771 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Apellis Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pegcetacoplan is the first listed.
NCT02461771 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02461771 about?
NCT02461771 is a clinical study titled "Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD". The objective of this study is to provide initial safety, tolerability and pharmacokinetics information of intravitreal administration of pegcetacoplan in order to support further development into larger Phase II studies for treatment of patients with AMD.
What is the current status of trial NCT02461771?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2015-01-28. Estimated completion is 2016-03-08.
What interventions are being tested in trial NCT02461771?
The interventions under investigation include: Pegcetacoplan (DRUG).
Who is sponsoring clinical trial NCT02461771?
This trial is sponsored by Apellis Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.